Phase 1b Trial Begins to Test Alector’s Immune-system Targeting Antibody AL003 in Alzheimer’s Patients

Phase 1b Trial Begins to Test Alector’s Immune-system Targeting Antibody AL003 in Alzheimer’s Patients
A Phase 1b trial has started dosing Alzheimer's patients with Alector’s candidate immune system-targeting therapy, called AL003, to evaluate its safety and tolerability, the company has announced. AL003 is an antibody which targets sialic acid binding Ig-like lectin 3 (SIGLEC 3, also known as CD33). SIGLEC 3 is found on a type of brain cell called microglia which act as the main form of immune defence in the central nervous system. The antibody works by binding to SIGLEC 3 and stopping it from functioning, which allows microglia to function normally and possibly ease the severity or progression of Alzheimer’s. SIGLEC 3 is also a known genetic risk factor for Alzheimer’s and mutations in this gene have been associated with an increased risk of developing Alzheimer's disease. “AL003 is intended to allow the brain’s immune system to simultaneously address multiple parallel pathologies involved in the progression of Alzheimer’s disease,” Arnon Rosenthal, PhD, CEO at Alector, said in a press release. Researchers are now initiating the second part of the INTERCEPT trial (NCT03822208). This placebo-controlled study is evaluating AL003's safety, tolerability, pharmacokinetics (essentially how the body affects a medicine), and pharmacodynamics (
Subscribe or to access all post and page content.